Drug-induced lupus (DIL) is an idiosyncratic side effect of treatments in which symptoms overlap with those of systemic lupus erythematosus (SLE). The spectrum of DIL constantly evolves with that of the pharmacopoeia. In this webinar you could find the current nosology of DIL, the definition for DIL, the epidemiology of DIL, the clinical and auto-antibody profile, and a small overview on the list of drugs, the pathogenesis, the treatment and prognosis.
More info about SLE can be found here: reconnet.ern-net.eu/disease-sle/
Speaker:
- Prof. Arnaud is full professor of Rheumatology at the Department of Rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune disease.
Following a MD degree from Université Pierre et Marie Curie (Paris) and a PhD in immunology at the same institution, Prof. Arnaud completed a fellowship program with a specialization in auto-immune diseases at Hôpital Pitié-Salpêtrière in Paris. He then pursued post-doctoral clinical research on systemic lupus at the Karolinska Institutet (Stockholm, Sweden) and was subsequently appointed full Professor of Medicine at Strasbourg University School of Medicine. His main research interests focus around the systematic evaluation of treatments for systemic diseases, with a specialization for the care of patients with lupus erythematosus and relapsing polychondritis. With his team, he has contributed to more than 150 research projects in the field of rare diseases. Prof. Arnaud is an active member of the French National Reference Center for Rare Autoimmune Diseases of Strasbourg, of the ERN ReCONNET and ERN RITA, and is the curator of a twitter account dedicated to SLE @Lupusreference